Patent application number | Description | Published |
20090074673 | Compositions and methods for producing cellular labels for nuclear magnetic resonance techniques - The disclosure provides, in part, compositions and methods for producing cellular labels for tracking cells by MRI. The disclosure provides, in part, methods for labeling, detecting and quantifying cell numbers in vivo. | 03-19-2009 |
20110110863 | COMPOSITIONS AND METHODS FOR PRODUCING EMULSIONS FOR NUCLEAR MAGNETIC RESONANCE TECHNIQUES AND OTHER APPLICATIONS - The disclosure provides, in part, compositions and methods for producing emulsions. In certain embodiments, emulsions of the disclosure can be used for the detection of inflammation and cell tracking using MRI. The disclosure provides, in part, methods for labeling, detecting and quantifying cell numbers in vivo. In certain embodiments, emulsions can be used as an artificial blood substitute | 05-12-2011 |
20130343999 | COMPOSITIONS AND METHODS FOR PRODUCING EMULSIONS FOR NUCLEAR MAGNETIC RESONANCE TECHNIQUES AND OTHER APPLICATIONS - The disclosure provides, in part, compositions and methods for producing emulsions. In certain embodiments, emulsions of the disclosure can be used for the detection of inflammation and cell tracking using MRI. The disclosure provides, in part, methods for labeling, detecting and quantifying cell members, in vivo. In certain embodiments, emulsions can be used as an artificial blood substrate. | 12-26-2013 |
Patent application number | Description | Published |
20080207883 | Platelet Derived Growth Factor (PDGF) Nucleic Acid Ligand Complexes - This invention discloses a method for preparing a complex comprised of a PDGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound by identifying a PDGF Nucleic Acid Ligand by SELEX methodology and associating the PDGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further discloses Complexes comprising one or more PDGF Nucleic Acid Ligands in association with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further includes a Lipid construct comprising a PDGF Nucleic Acid Ligand or Complex and methods for making the same. | 08-28-2008 |
20080227808 | Substituted Phenylether-Thienopyridone Compounds With Antibacterial Activity - Novel bicyclic heteroaromatic compounds are provided that are inhibitors of bacterial methionyl tRNA synthetase (MetRS). Compounds of the invention generally have a left hand side phenylether constituent and a right hand side thienopyridone constituent. Also disclosed are methods for their preparation and their use in therapy as antibacterial agents, particularly as anti- | 09-18-2008 |
20090075922 | Nucleic Acid Ligands Which Bind to Hepatocyte Growth Factor/Scatter Factor (HGF/SF) or its Receptor c-met - The invention provides nucleic acid ligands to hepatocyte growth factor/scatter factor (HGF) and its receptor c-met. The nucleic acid ligands of the instant invention are isolated using the SELEX method. SELEX is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The nucleic acid ligands of the invention are useful as diagnostic and therapeutic agents for diseases in which elevated HGF and c-met activity are causative factors. | 03-19-2009 |
20090163536 | METHODS AND COMPOUNDS FOR TREATMENT OF CLOSTRIDIUM BASED INFECTION - Methionyl tRNA synthetase inhibitors (MetRS) are provided for use in therapy as antibacterial agents in | 06-25-2009 |
20100028862 | BACTERIAL REPLICATION SYSTEMS AND METHODS - Reconstituted bacterial replication assemblies and methods for their use are provided. | 02-04-2010 |
20100029922 | Platelet Derived Growth Factor (PDGF) Nucleic Acid Ligand Complexes - This invention discloses a method for preparing a complex comprised of a PDGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound by identifying a PDGF Nucleic Acid Ligand by SELEX methodology and associating the PDGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further discloses Complexes comprising one or more PDGF Nucleic Acid Ligands in association with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further includes a Lipid construct comprising a PDGF Nucleic Acid Ligand or Complex and methods for making the same. | 02-04-2010 |
20110212030 | Nucleic Acid Ligand Complexes - This invention discloses a method for preparing a therapeutic or diagnostic complex comprised of a nucleic acid ligand and a lipophilic compound or non-immunogenic, high molecular weight compound by identifying a nucleic acid ligand by SELEX methodology and associating the nucleic acid ligand with a lipophilic compound or a non-immunogenic, high molecular weight compound. The invention further discloses complexes comprising one or more nucleic acid ligands in association with a lipophilic compound or non-immunogenic, high molecular weight compound. | 09-01-2011 |
20110275794 | 5-POSITION MODIFIED PYRIMIDINES AND THEIR USE - The present disclosure relates to the field of nucleic acid chemistry, specifically to 5-position modified uridines as well as phosphoramidite and triphosphate derivatives thereof. The present disclosure also relates to methods of making and using the same. | 11-10-2011 |
20120231467 | Aptamers for C. Difficile Diagnostics - The present disclosure relates generally to the field of nucleic acids and, more particularly, to aptamers capable of binding to toxins produced by | 09-13-2012 |
20130116150 | Lung Cancer Biomarkers and Uses Thereof - The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of lung cancer. In one aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose lung cancer or permit the differential diagnosis of pulmonary nodules as benign or malignant. In another aspect, methods are provided for diagnosing lung cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 18, Table 20, or Table 21, wherein the individual is classified as having lung cancer, or the likelihood of the individual having lung cancer is determined, based on the at least one biomarker value. | 05-09-2013 |
20140058076 | 5-POSITION MODIFIED PYRIMIDINES AND THEIR USE - The present disclosure relates to the field of nucleic acid chemistry, specifically to 5-position modified uridines as well as phosphoramidite and triphosphate derivatives thereof. The present disclosure also relates to methods of making and using the same. | 02-27-2014 |
20140155411 | Tuberculosis Biomarkers and Uses Thereof - The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection, treatment and diagnosis of tuberculosis (TB). In one aspect, the present application includes the identification of biomarkers that can be used alone or in various combinations for the detection of TB, including those set forth in Tables 1, 2, 4, 5, and 8 to 12. In another aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose or prognose TB or follow treatment response. In another aspect, methods are provided for diagnosing TB in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Tables 1, 2, 4, 5, and 8 to 12, wherein the individual is classified as having TB, or the likelihood of the individual having TB is determined, based on the at least one biomarker value. | 06-05-2014 |
20140315986 | APTAMERS THAT BIND TO IL-6 AND THEIR USE IN TREATING OR DIAGNOSING IL-6 MEDIATED CONDITIONS - Aptamers that bind IL-6 are provided. Pharmaceutical compositions comprising IL-6 aptamers are provided, as well as methods of treating conditions using the aptamers are also provided. | 10-23-2014 |
20150031585 | Multiaptamer Target Detection - Described herein are compositions comprising a first aptamer, second aptamer and a target that are capable of forming a ternary complex, and wherein the first aptamer and the second aptamer comprise C-5 pyrimidine modification schemes that are different, and methods of making and using such compositions. | 01-29-2015 |